Fatty liver medical therapy

Jump to navigation Jump to search

Fatty Liver Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fatty Liver from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fatty liver medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fatty liver medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fatty liver medical therapy

CDC on Fatty liver medical therapy

Fatty liver medical therapy in the news

Blogs on Fatty liver medical therapy

Directions to Hospitals Treating Fatty liver

Risk calculators and risk factors for Fatty liver medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that diet, exercise, and especially antiglycemic drugs may alter the course of the disease. A randomized controlled trial found that pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis.[1]

Elderly may not benefit from treatment[2].

Medical Therapy

References

  1. Belfort R, Harrison SA, Brown K; et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584.
  2. van Kleef LA, Sonneveld MJ, Kavousi M, Ikram MA, de Man RA, de Knegt RJ (2022). "Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study". Hepatology. doi:10.1002/hep.32635. PMID 35753042 Check |pmid= value (help).

Template:WS Template:WH